Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention
NCT04966507 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89
Last updated 2026-02-13
Summary
This study aims to determine acceptability and preliminary efficacy of daily use of an antibacterial mouthwash as compared to a placebo mouthwash in reducing the incidence of pharyngeal gonorrhea among a cohort of HIV-positive and high risk HIV-negative men.
Investigators plan to test the following hypotheses:
1. Participants will maintain a high level of adherence and satisfaction with daily mouthwash use. Furthermore, the investigators hypothesize that barriers to adherence will include structural factors such as unstable housing and individual level factors such as substance use.
2. Participants receiving the antibacterial mouthwash will have a lower incidence of pharyngeal gonorrhea as compared to participants receiving the placebo mouthwash. Furthermore, the investigators hypothesize that these reductions will remain even after adjusting for other factors such as HIV-status and substance use.
Conditions
- Gonorrhea
Interventions
- DRUG
-
Listerine Antiseptic Mouthwash Product
COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
- DRUG
-
Biotene Mouthwash
Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
University of California, Los Angeles
lead OTHER
Principal Investigators
-
Marjan Javanbakht · University of California, Los Angeles
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-17
- Primary Completion
- 2025-05-16
- Completion
- 2025-12-12
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women
NCT00442910 ·Status: COMPLETED ·Phase: PHASE1
-
Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females
NCT00706368 ·Status: UNKNOWN ·Phase: NA
-
Safety and Acceptability of a Vaginal Microbicide
NCT00111943 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
NCT01490671 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel
NCT00028132 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis
NCT02709005 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide
NCT00213031 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women
NCT02875119 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Nonoxynol-9 (N-9) and HIV Infection
NCT00000926 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
NCT04553068 ·Status: COMPLETED ·Phase: PHASE3
-
Study of UC-781 Vaginal Microbicide
NCT00132444 ·Status: COMPLETED ·Phase: PHASE1
-
Rectal Safety and Acceptability Study of Tenofovir 1% Gel
NCT01232803 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand
NCT00213057 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women
NCT00136643 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide
NCT00441909 ·Status: COMPLETED ·Phase: PHASE1
-
Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms
NCT02569697 ·Status: COMPLETED ·Phase: PHASE1
-
Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis
NCT02185456 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis
NCT02905890 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of BufferGel in Women
NCT00000927 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
NCT02237950 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
NCT01812889 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
NCT00303576 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
NCT00262106 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308046 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of BufferGel and PRO 2000/5 Gel in Men
NCT00016536 ·Status: COMPLETED ·Phase: PHASE1